



Vertex Pharmaceuticals Incorporated
130 Waverly Street • Cambridge, MA 02139-4242
Tel. 617.444.6100 • Fax 617.444.6483
<http://www.vpharm.com>

RECEIVED
CENTRAL FAX CENTER

DEC 08 2005

Fax Message


TO: USPTO
PATENT NO.: 10/799,507
FAX: (571) 273-8300
FROM: Karen E. Brown
DATE: December 8, 2005
SUBJECT: Attorney Docket No. VPI/03-01 US
Supplemental IDS
TOTAL # OF PAGES: 26

Message or Comment

Please see attached documents.

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this correspondence and any documents attached hereto, are being transmitted via facsimile to the United States Patent and Trademark Office, Facsimile Number: (571) 273-8300 on December 8 2005.


Lisa M. Romano

If any problems occur with this fax transmittal, please call (617) 444-6164 immediately.

FAX Number (617) 444-6483 Legal Department

CONFIDENTIALITY NOTICE

The information and the documents transmitted by this telecopy are privileged and contain confidential information intended only for the person (s) names above. Any other distribution, copying or disclosure is strictly prohibited. If you have received this telecopy in error, please notify us immediately by telephone and return the original to us without making a copy.

Docket No.: VPI/03-01 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
CENTRAL FAX CENTER

DEC 08 2005

Application No.: 10/799,507
Confirmation No.: 8237
Filing Date: March 12, 2004
Examiner: Deepak R. Rao
Group Art Unit: 1624
Applicants: Young-Choon Moon
For: 4-SUBSTITUTED-5-CYANO-1H-PYRIMIDIN-6-(THI)ONES
AS GSK-3 INHIBITORS

December 8, 2005
Cambridge, Massachusetts

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER FOR SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT

- (a) Pursuant to 37 C.F.R. §1.56, it is requested that the documents listed on the accompanying Form 1449/PTO be considered and made of record in the above-identified patent application.

- ☒ Copy(ies) of references Citation No(s). C1-C2 is attached
- ☐ Copy(ies) of references Citation No(s). _____ was/were filed in application U.S. Application No(s). _____ filed _____, from which this application claims priority under 35 U.S.C. § 120.).
- ☐ A copy of the International Search Report received in the corresponding PCT Application No. _____ is attached herewith.

- (b) ☐ No fee is believed due because:

- ☐ The Information Disclosure Statement is being filed within three (3) months of the filing date of the application.
- ☐ The Information Disclosure Statement is being concurrently filed with the above-identified application.
- ☐ The Information Disclosure Statement is being concurrently filed with a Request for Continued Examination (RCE).

12/09/2005 SFELEKE1 00000076 500725 10799507

01 FC:1806 180.00 DA

BEST AVAILABLE COPY

12/08/2005 13:45 FAX

003/026


APPLICANTS: Young-Choon Moon
U.S.S.N.: 10/799,507

- ☐ The Information Disclosure Statement is being filed prior to the mailing of a first Office Action on the merits.
- (c) ☒ The Information Disclosure Statement is being filed before the mailing date of any final action, notice of allowance or an action that otherwise closes prosecution; and
- ☐ Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- ☐ No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement; or
- ☒ The Director is hereby authorized to charge \$180.00 to Deposit Account No. 50-0725.
- (d) ☐ The Information Disclosure Statement is being filed on or before the payment of the issue fee; and
- ☐ Each item of information contained in the Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement; or
- ☐ No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement; and
- ☐ The Director is hereby authorized to charge \$180.00 to Deposit Account No. 50-0725.

APPLICANTS: Young-Choon Moon
U.S.S.N.: 10/799,507

☒ The Director is hereby authorized to charge any additional fees that may be required for the Information Disclosure Statement, or credit any overpayment to Deposit Account No. 50-0725. A DUPLICATE COPY OF THIS LETTER IS ATTACHED.

Respectfully submitted,


Karen E. Brown, Reg. No. 43,866
Attorney for Applicants
c/o Vertex Pharmaceuticals Incorporated
130 Waverly Street
Cambridge, Massachusetts 02139
Tel: (617) 444-6467
Fax: (617) 444-6483
Customer No. 2791

Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	10/799,507
	Filing Date	March 12, 2004
	First Named Inventor	Young Choon-Moon
	Group Art Unit	1624
	Examiner Name	Deepak R. Rao
	Attorney Docket Number	VPI/03-01 US

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Publication Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS					
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No

OTHER NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C1	Gary W. Cline et al, "Effects of a Novel Glycogen Synthase Kinase-3 Inhibitor on Insulin-Stimulated Glucose Metabolism in Zucker Diabetic Fatty (fa/fa) Rats", <i>Diabetes</i> , 51: 2903-2910 (2002)
	C2	Erik J. Henriksen et al, "Modulation of Muscle Insulin Resistance by Selective Inhibition of GSK-3 in Zucker Diabetic Fatty Rats", <i>American Journal of Physiology Endocrinology and Metabolism</i> , 284: E892-E900 (2003).

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, U.S.S.N. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.